Apoptosis block as a barrier to effective therapy in non small cell lung cancer  

作　　者：Ian Paul J Mark Jones 

机构地区：[1]Department of Cardiothoracic Surgery, Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, United Kingdom

出　　处：《World Journal of Clinical Oncology》2014年第4期588-594,共7页世界临床肿瘤学杂志（英文版）

摘　　要：Lung cancer, is the most common cause of cancer death in men and second only to breast cancer in women. Currently, the first line therapy of choice is platinumbased combination chemotherapy. A therapeutic plateau has been reached with the prognosis for patients with advanced non-small cell lung cancer(NSCLC) remaining poor. New biomarkers of prognosis as well as new therapies focusing on molecular targets are emerging helping to identify patients who are likely to benefit from therapy. Despite this, drug resistance remains the major cause for treatment failure. In this article we review the role of apoptosis in mediating drug resistance in NSCLC. Better understanding of this fundamental biological process may provide a rationale for overcoming the current therapeutic plateau.Lung cancer, is the most common cause of cancer death in men and second only to breast cancer in women. Currently, the first line therapy of choice is platinumbased combination chemotherapy. A therapeutic plateau has been reached with the prognosis for patients with advanced non-small cell lung cancer(NSCLC) remaining poor. New biomarkers of prognosis as well as new therapies focusing on molecular targets are emerging helping to identify patients who are likely to benefit from therapy. Despite this, drug resistance remains the major cause for treatment failure. In this article we review the role of apoptosis in mediating drug resistance in NSCLC. Better understanding of this fundamental biological process may provide a rationale for overcoming the current therapeutic plateau.

关 键 词：APOPTOSIS Lung cancer ADJUVANT THERAPY MITOCHONDRIA BAX BAK BCL2 

分 类 号：R734.2[医药卫生—肿瘤]